Alerts will be sent to your verified email
Verify EmailSANJIVIN
|
Sanjivani Paranteral
|
Quest Laboratories
|
Speciality Medicines
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Quarterly Sales Volume - Injectables
|
n/a | n/a | n/a |
|
Quarterly Sales Volume - Orals
|
n/a | n/a | n/a |
|
Quarterly Sales Volume - Nutraceuticals
|
n/a | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
14.47 % | 27.48 % | 38.23 % |
|
5yr average Equity Multiplier
|
-1.07 | 2.66 | 2.01 |
|
5yr Average Asset Turnover Ratio
|
1.28 | 1.38 | 2.86 |
|
5yr Avg Net Profit Margin
|
11.86 % | 8.5 % | 9.1 % |
|
Price to Book
|
3.67 | 2.01 | 0.0 |
|
P/E
|
26.08 | 13.31 | 21.33 |
|
5yr Avg Cash Conversion Cycle
|
9.84 Days | 100.68 Days | 128.49 Days |
|
Inventory Days
|
50.77 Days | 35.64 Days | 60.0 Days |
|
Days Receivable
|
53.66 Days | 95.62 Days | 63.56 Days |
|
Days Payable
|
138.53 Days | 124.41 Days | 27.57 Days |
|
5yr Average Interest Coverage Ratio
|
21.37 | 15.83 | 26.44 |
|
5yr Avg ROCE
|
-90.78 % | 36.4 % | 54.65 % |
|
5yr Avg Operating Profit Margin
|
14.73 % | 12.5 % | 13.99 % |
|
5 yr average Debt to Equity
|
-0.19 | 0.33 | 0.4 |
|
5yr CAGR Net Profit
|
12.42 % | 83.07 % | 42.22 % |
|
5yr Average Return on Assets
|
15.34 % | 10.79 % | 18.23 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
31.26 % | 66.78 % | 43.43 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
1.38 % | 0.95 % | 43.43 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Sanjivani Paranteral
|
Quest Laboratories
|
Speciality Medicines
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Location Wise Break-Up
|